Last reviewed · How we verify
NCT03956706
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
NA trial testing Stereotactic Radiosurgery in Glioblastoma. Withdrawn.
1 September 2022
Quick facts
| Lead sponsor | Northwell Health |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 24 December 2018 |
| Primary completion | 1 September 2022 |
| Estimated completion | 1 September 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stereotactic Radiosurgery
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
- Astrocytoma, Grade III — all drugs for Astrocytoma, Grade III →
- Astrocytoma, Grade IV — all drugs for Astrocytoma, Grade IV →
- Malignant Glioma — all drugs for Malignant Glioma →
Sponsor
Northwell Health — full company profile →
Who can join
18 and older, any sex, with Glioblastoma or Astrocytoma, Grade III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Several investigations suggest neural stem cells located in the subventricular region play an active role in promoting or even initiating cortical malignant glioma growth. Although normal appearing on neuroimaging, surgical specimens taken from this region show it contains malignant glioma stem-like cells. Some retrospective analyses found patients who received radiation therapy to this region during standard of care treatments lived longer than patients who did not. The investigator's study hypothesizes (1) stereotactic radiosurgery of cancer stem-like cells in these regions will be well tolerated during standard of care therapy, (2) focused stereotactic radiosurgery will be more effective in destroying cancer stem cells than conventional radiation therapy, and (3) treatment will improve malignant glioma survival.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The adaptive transition of glioblastoma stem cells and its implications on treatments.
Wang Z, Zhang H, Xu S, Liu Z, et al · · 2021 · cited 101× · PMID 33753720 · DOI 10.1038/s41392-021-00491-w -
Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges.
Piper K, DePledge L, Karsy M, Cobbs C. · · 2021 · cited 38× · PMID 33718170 · DOI 10.3389/fonc.2021.615704 -
Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.
Srivastava R, Dodda M, Zou H, Li X, et al · · 2023 · cited 15× · PMID 37166370 · DOI 10.1089/ars.2022.0187
Verify or expand the search:
- PubMed search for NCT03956706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stereotactic Radiosurgery
Trials testing the same drug.
- NCT06649058 — EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study · Phase 2 · recruiting
- NCT06287515 — Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain · Phase 1 · recruiting
- NCT06500455 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to · Phase 3 · recruiting
- NCT06204315 — Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compres · Phase 2 · recruiting
- NCT06248606 — Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases · Phase 2 · recruiting
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Northwell Health trials
Trials by the same sponsor.
- NCT07253662 — Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Aden · Phase 1 · recruiting
- NCT07191041 — Emotional Urinary Tract Infection · not yet recruiting
- NCT07254091 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer · EARLY_PHASE1 · recruiting
- NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
- NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03956706 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwell Health
- Last refreshed: 15 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03956706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing